Abstract
Cancer is a complex series of stepwise genetic mutations and epigenetic modifications resulting in characteristic phenotypic changes in the transformed neoplastic cells (“cancer hallmarks”). Some of the altered genes become “oncogenes,” a gene whose presence induces a cascade of biologic events that promote malignant transformation of the cell, causing unchecked proliferation and spread (metastases) widely in the body with the potential to disrupt and even destroy the normal tissue phenotype; this leads to loss of essential normal functions and ultimately, if not effectively treated, death of the host. Locally, at both primary and metastatic sites, cancer cells recruit normal host tissues to create a favorable environment for their survival and replication. Fibrocytes and collagen-producing cells provide structure for the tumor cells to form a stroma, also called tumor microenvironment (TME). Cancer cells interact with this stroma through paracrine signals that alter the stromal phenotype to be maximally supportive of the tumor mass. Endothelial cells are recruited to form blood vessels prompting tumor blood flow, providing oxygen and nutrients for growth. Tumor blood vessels have incomplete endothelium, making the vessels leaky. This allows large molecules and immune cells to pass readily into the tumor interstitium, often fostering an environment within the mass that resists immunologic attack.
Hallmarks of cancer include rapid proliferation, a characteristic metabolism, immortality, resistance to apoptosis, resistance to suppression of proliferation, metastatic behavior, and resistance to immunologic attack. There is growing evidence that the individual cellular phenotype in cancers is continuously evolving based on epigenetic action (“lineage plasticity”), during which multiple genes may be co-opted from usually quiescent tissue development pathways. These changes sometimes promote intrinsic and extrinsic resistance to cancer treatments. The tumor mass may locally invade surrounding tissue, causing pain and organ dysfunction. Cells and groups of cells leave the primary mass as single cells or in clusters and metastasize to distant organs, often in an organ selective manner.
Molecular imaging (MI) and its therapeutic twin molecular targeted radiotherapy (MTR) are rapidly evolving into major determinants for diagnostic and treatment decisions in clinical oncology. Molecular imaging offers quantitative detection of the molecules and molecular-based events that are fundamental to the malignant state in vivo in living subjects. MTR exploits the unique biochemical specificity of cancer-related molecular targets to deliver focused radiation to cancer cells. In this chapter, we shall learn how the discovery of key biomolecules and biochemical processes central to cancer genesis and progression are being mirrored in successful development of practical diagnostic and therapeutic radiopharmaceuticals useful for clinical care.
These advances in available radiodrugs occur in the context of the ever-expanding capability of nuclear imaging methods, with improved resolution, sensitivity, and quantitative power that permits real-time functional imaging at the tumor and tissue level. Clinical PET and SPECT imaging is now “fusion” imaging, whereby an anatomic context comes directly from high-resolution cross-sectional imaging equipment, particularly CT and MRI; fusion images facilitate staging and treatment response monitoring for oncology. Additionally, high-speed computer-based analytic platforms convert radioactive counts into functional images representing key tumor-specific biochemical processes.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
Abbreviations
- ABC:
-
ATP-binding cassette, a transport system superfamily
- ABL:
-
Abelson murine leukemia
- AKT:
-
Protein kinase B
- AML:
-
Acute myeloid leukemia
- APC:
-
Antigen-presenting cell
- AR:
-
Androgen receptor
- ASCO:
-
American Society of Clinical Oncology
- ATP:
-
Adenosine triphosphate
- BRAF:
-
Gene encoding for the B-Raf protein, a serine/threonine-protein kinase; the gene is also known as the proto-oncogene B-Raf and v-Raf murine sarcoma viral oncogene homolog B
- BRCA1:
-
Breast cancer type 1 susceptibility protein
- BRCA2:
-
Breast cancer type 2 susceptibility protein
- BRS:
-
BRAF-RAS score
- BSI:
-
Bone scan index
- CA9:
-
Carbonic anhydrase 9 (or carbonic anhydrase IX, CAIX)
- c-Kit:
-
Gene encoding for tyrosine-protein kinase kit (or CD117), also known as Mast/stem cell growth factor receptor (SCFR)
- CML:
-
Chronic myeloid leukemia
- CR:
-
Complete response to therapy
- CRPC:
-
Castrate-resistant prostate cancer
- CT:
-
X-ray computed tomography
- CTL:
-
Cytotoxic T cell
- CTLA4:
-
Cytotoxic T-lymphocyte antigen 4, also known as CD152
- CTLC:
-
Cutaneous T-cell lymphoma
- DHT:
-
Dihydrotestosterone
- DOTA:
-
1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid
- DOTATATE:
-
DOTA-Tyr3-octreotate
- EGFR:
-
Epidermal growth factor receptor; the mutated form EGFRvIII plays a prominent role in tumorigenesis and proangiogenic signaling
- EORTC:
-
European Organisation for Research and Treatment of Cancer
- EPR:
-
Extravasation and passive retention
- ERK:
-
Extracellular signal-regulated kinase
- [18F]FDG:
-
2-Deoxy-2-[18F]fluoro-d-glucose
- 18F-FACBC:
-
Anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid
- 18F-FDHT:
-
16β-18F-Fluoro-5-dihydrotestosterone
- 18F-FGln:
-
18F-Fluoroglutamine
- 18F-FLT:
-
2-18F-Fluoro-l-thymidine
- 18F-MISO:
-
18F-Fluoromisonidazole
- FAPI:
-
Fibroblast activation protein inhibitor
- FDHT:
-
Flouro-di-hydrotestrone, an androgen targeting drug used when labeled with Flourine 18 for PET
- 68Ga-PSMA:
-
Glu-urea-Lys-(Ahx)-[68Ga(HBED-CC)]
- GIST:
-
Gastrointestinal stromal tumor
- 2-HG:
-
2-Hydroxyglutarate
- H&E:
-
Hematoxylin and eosin staining
- HER2:
-
Human epidermal growth factor receptor 2, also known as receptor tyrosine-protein
- HIF-1:
-
Hypoxia-inducible factor
- HK2:
-
Hexokinase 2
- hsvTK:
-
Herpes simplex virus-1 thymidine kinase
- IDH1:
-
Isocitrate dehydrogenase 1, a cytoplasmic enzyme
- IDH1:
-
Isocitrate dehydrogenase enzymes
- IDH2:
-
Isocitrate dehydrogenase 2, a mitochondrial enzyme
- IL2:
-
Interleukin 2
- Markov chain:
-
A mathematical concept describing a transition from one state to another by probability-driven rules used to describe transitions of cell types from one maturation state to another along a development path toward a mature cellular end-state
- MEK:
-
Mitogen-activated protein kinase
- MI:
-
Molecular imaging
- MRI:
-
Magnetic resonance imaging
- MSKCC:
-
Memorial Sloan-Kettering Cancer Center
- mTOR:
-
Mammalian target of rapamycin
- MTV:
-
Metabolizing tumor volume
- Myc:
-
Regulator gene that encodes for a transcription factor (also known as c-Myc)
- NAALADase:
-
N-Acetylated-alpha-linked-acidic dipeptidase, also known as glutamate carboxypeptidase II
- NADPH:
-
Nicotinamide adenine dinucleotide phosphate
- NIH:
-
United States National Institutes of Health
- NSCLC:
-
Non–small cell lung cancer
- p53:
-
Tumor protein p53, also known as cellular tumor antigen p53, phosphoprotein p53, tumor suppressor p53, antigen NY-CO-13, or transformation-related protein 53 (TRP53)
- PARP:
-
Poly adenosine diphosphate ribose polymerase
- PARPi:
-
Poly adenosine diphosphate ribose polymerase inhibitor
- PD-1:
-
Programmed cell death protein 1, also known as CD279
- PERCIST:
-
Positron emission tomography response criteria in solid tumors
- PET:
-
Positron emission tomography
- PET/CT:
-
Positron emission tomography/Computed tomography
- PI13K:
-
Phosphoinositide 3-kinase
- PI3K/AKT/mTOR:
-
Intracellular signaling pathway regulating the cell cycle
- PR:
-
Partial response
- PSMA:
-
Prostate-specific membrane antigen
- PTEN:
-
Gene encoding for the phosphatase and tensin homolog protein, a tumor suppressor; PTEN deletions indicate a poor prognosis
- RAI:
-
Radioactive iodine (most often 131I) used for therapy
- RAIR:
-
RAI refractory (thyroid cancer)
- Ras:
-
Oncogene regulating signaling cascades
- RB:
-
Gene encoding for the retinoblastoma protein
- RCHOP:
-
Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone
- RECIST:
-
Response evaluation criteria in solid tumors
- RNAseq:
-
Rapid RNA sequencing to detect gene sequences activated in a genome
- RTK:
-
Receptor tyrosine kinase
- SCLC:
-
Small-cell lung cancer
- STEAP:
-
Family of transmembrane epithelial antigens of prostate comprising six members
- SUL:
-
Lean body mass corrected standard uptake value
- SULpeak:
-
Lean body mass corrected standard uptake value at voxels of maximum
- SUV:
-
Standardized uptake value
- SUVmax:
-
Standardized uptake value at point of maximum
- SUVpeak:
-
Standardized uptake value at voxels of maximum, based on correction for lean body mass
- TCR:
-
T-cell receptor
- TDS:
-
Thyroid differentiation score
- TIL:
-
Tumor-infiltrating lymphocyte
- TLG:
-
Total lesion glycolysis
- VEGF:
-
Vascular endothelial growth factor
- VEGFR:
-
Vascular endothelial growth factor receptor
- VHL:
-
Von Hippel-Lindau
References
Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz Jr LA, Kinzler KW. Cancer genome landscapes. Science. 2013;339(6127):1546–58. https://doi.org/10.1126/science.1235122.
Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100(1):57–70. https://doi.org/10.1016/s0092-8674(00)81683-9.
Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma AA, et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer. 1999;35:1773–82.
Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50 Suppl 1(0161–5505 (Print)):122S–50S. https://doi.org/10.2967/jnumed.108.057307.
Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285(21):1182–6. https://doi.org/10.1056/NEJM197111182852108.
Ferrara N, Adamis AP. Ten years of anti-vascular endothelial growth factor therapy. Nat Rev Drug Discov. 2016;15(6):385–403. https://doi.org/10.1038/nrd.2015.17.
Gaykema SB, Brouwers AH, Lub-de Hooge MN, Pleijhuis RG, Timmer-Bosscha H, Pot L, et al. 89Zr-bevacizumab PET imaging in primary breast cancer. J Nucl Med. 2013;54(7):1014–8. https://doi.org/10.2967/jnumed.112.117218.
Zhu Z, Miao W, Li Q, Dai H, Ma Q, Wang F, et al. 99mTc-3PRGD2 for integrin receptor imaging of lung cancer: a multicenter study. J Nucl Med. 2012;53(5):716–22. https://doi.org/10.2967/jnumed.111.098988.
Stacy MR, Maxfield MW, Sinusas AJ. Targeted molecular imaging of angiogenesis in PET and SPECT: a review. Yale J Biol Med. 2012;85(1):75–86.
Beer AJ, Grosu AL, Carlsen J, Kolk A, Sarbia M, Stangier I, et al. [18F]galacto-RGD positron emission tomography for imaging of alphavbeta3 expression on the neovasculature in patients with squamous cell carcinoma of the head and neck. Clin Cancer Res. 2007;13(22 Pt 1):6610–6. https://doi.org/10.1158/1078-0432.CCR-07-0528.
Schliemann C, Neri D. Antibody-based targeting of the tumor vasculature. Biochim Biophys Acta. 2007;1776(2):175–92. https://doi.org/10.1016/j.bbcan.2007.08.002.
Rajendran JG, Wilson DC, Conrad EU, Peterson LM, Bruckner JD, Rasey JS, et al. [18F]FMISO and [18F]FDG PET imaging in soft tissue sarcomas: correlation of hypoxia, metabolism and VEGF expression. Eur J Nucl Med Mol Imaging. 2003;30(5):695–704. https://doi.org/10.1007/s00259-002-1096-7.
Garcia-Barros M, Paris F, Cordon-Cardo C, Lyden D, Rafii S, Haimovitz-Friedman A, et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science. 2003;300(5622):1155–9. https://doi.org/10.1126/science.1082504.
Levchenko A, Mehta BM, Niu X, Kang G, Villafania L, Way D, et al. Intercellular transfer of P-glycoprotein mediates acquired multidrug resistance in tumor cells. Proc Natl Acad Sci U S A. 2005;102(6):1933–8. https://doi.org/10.1073/pnas.0401851102.
McArthur GA, Puzanov I, Amaravadi R, Ribas A, Chapman P, Kim KB, et al. Marked, homogeneous, and early [18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma. J Clin Oncol. 2012;30(14):1628–34. https://doi.org/10.1200/JCO.2011.39.1938.
Couzin-Frankel J. Breakthrough of the year 2013. Cancer immunotherapy. Science. 2013;342(6165):1432–3. https://doi.org/10.1126/science.342.6165.1432.
Page DB, Postow MA, Callahan MK, Allison JP, Wolchok JD. Immune modulation in cancer with antibodies. Annu Rev Med. 2014;65(1545-326X (Electronic)):185–202. https://doi.org/10.1146/annurev-med-092012-112807.
Wolchok JD, Weber JS, Hamid O, Lebbe C, Maio M, Schadendorf D, et al. Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trials. Cancer Immun. 2010;10(1424–9634 (Electronic)):9.
Fares J, Fares MY, Khachfe HH, Salhab HA, Fares Y. Molecular principles of metastasis: a hallmark of cancer revisited. Signal Transduct Target Ther. 2020;5(1):28. https://doi.org/10.1038/s41392-020-0134-x.
Kang Y, He W, Tulley S, Gupta GP, Serganova I, Chen CR, et al. Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. Proc Natl Acad Sci U S A. 2005;102(39):13909–14. https://doi.org/10.1073/pnas.0506517102.
Minn AJ, Kang Y, Serganova I, Gupta GP, Giri DD, Doubrovin M, et al. Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors. J Clin Invest. 2005;115(1):44–55. https://doi.org/10.1172/JCI22320.
Bos PD, Zhang XH, Nadal C, Shu W, Gomis RR, Nguyen DX, et al. Genes that mediate breast cancer metastasis to the brain. Nature. 2009;459(7249):1005–9. https://doi.org/10.1038/nature08021.
Comen E, Norton L, Massague J. Clinical implications of cancer self-seeding. Nat Rev Clin Oncol. 2011;8(6):369–77. https://doi.org/10.1038/nrclinonc.2011.64.
Kim MY, Oskarsson T, Acharyya S, Nguyen DX, Zhang XH, Norton L, et al. Tumor self-seeding by circulating cancer cells. Cell. 2009;139(7):1315–26. https://doi.org/10.1016/j.cell.2009.11.025.
Warburg O. On the origin of cancer cells. Science. 1956;123:309–14. https://doi.org/10.1126/science.123.3191.309.
Fantin VR, St-Pierre J, Leder P. Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell. 2006;9:425–34.
Deberardinis RJ, Sayed N, Ditsworth D, Thompson CB. Brick by brick: metabolism and tumor cell growth. Curr Opin Genet Dev. 2008;18(1):54–61. https://doi.org/10.1016/j.gde.2008.02.003.
Hsu PP, Sabatini DM. Cancer cell metabolism: Warburg and beyond. Cell. 2008;134(5):703–7. https://doi.org/10.1016/j.cell.2008.08.021.
Wise DR, DeBerardinis RJ, Mancuso A, Sayed N, Zhang XY, Pfeiffer HK, et al. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc Natl Acad Sci U S A. 2008;105(48):18782–7. https://doi.org/10.1073/pnas.0810199105.
Thompson CB. Metabolic enzymes as oncogenes or tumor suppressors. N Engl J Med. 2009;360:813–5.
Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009;462(7274):739–44. https://doi.org/10.1038/nature08617.
Zasadny KR, Wahl RL. Standardized uptake values of normal tissues at PET with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose: variations with body weight and a method for correction. Radiology. 1993;189:847–50.
Wibmer AG, Morris MJ, Gonen M, Zheng J, Hricak H, Larson SM, et al. Quantification of metastatic prostate cancer whole-body tumor burden with FDG pet parameters and associations with overall survival after first line Abiraterone or Enzalutamide: a single-center retrospective cohort study. J Nucl Med. 2021;62(8):1050–6. https://doi.org/10.2967/jnumed.120.256602.
Setty M, Kiseliovas V, Levine J, Gayoso A, Mazutis L, Pe'er D. Characterization of cell fate probabilities in single-cell data with Palantir. Nat Biotechnol. 2019;37:451–60.
Beltran H, Hruszkewycz A, Scher HI, Hildesheim J, Isaacs J, Yu EY, et al. The role of lineage plasticity in prostate cancer therapy resistance. Clin Cancer Res. 2019;25(23):6916–24. https://doi.org/10.1158/1078-0432.CCR-19-1423.
Davies AH, Beltran H, Zoubeidi A. Cellular plasticity and the neuroendocrine phenotype in prostate cancer. Nat Rev Urol. 2018;15(5):271–86. https://doi.org/10.1038/nrurol.2018.22.
Quintanal-Villalonga Á, Chan JM, Yu HA, Pe'er D, Sawyers CL, Sen T, et al. Lineage plasticity in cancer: a shared pathway of therapeutic resistance. Nat Rev Clin Oncol. 2020;17:360–71.
Beattie BJ, Smith-Jones PM, Jhanwar YS, Schöder H, Schmidtlein CR, Morris MJ, et al. Pharmacokinetic assessment of the uptake of 16beta-18F-fluoro-5alpha-dihydrotestosterone (FDHT) in prostate tumors as measured by PET. J Nucl Med. 2010;51:183–92.
Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet. 2010;375(9724):1437–46. https://doi.org/10.1016/S0140-6736(10)60172-9.
Fox JJ, Morris MJ, Larson SM, Schoder H, Scher HI. Developing imaging strategies for castration resistant prostate cancer. Acta Oncol. 2011;50 Suppl 1(1651–226X (Electronic)):39–48. https://doi.org/10.3109/0284186X.2011.572914.
Fox JJ, Autran-Blanc E, Morris MJ, Gavane S, Nehmeh S, Van Nuffel A, et al. Practical approach for comparative analysis of multilesion molecular imaging using a semiautomated program for PET/CT. J Nucl Med. 2011;52(11):1727–32. https://doi.org/10.2967/jnumed.111.089326.
Ulmert D, Evans MJ, Holland JP, Rice SL, Wongvipat J, Pettersson K, et al. Imaging androgen receptor signaling with a radiotracer targeting free prostate-specific antigen. Cancer Discov. 2012;2(4):320–7. https://doi.org/10.1158/2159-8290.CD-11-0316.
Evans MJ, Smith-Jones PM, Wongvipat J, Navarro V, Kim S, Bander NH, et al. Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen. Proc Natl Acad Sci U S A. 2011;108(23):9578–82. https://doi.org/10.1073/pnas.1106383108.
Pandit-Taskar N, O’Donoghue JA, Ruan S, Lyashchenko SK, Carrasquillo JA, Heller G, et al. First-in-human imaging with 89Zr-Df-IAB2M anti-PSMA minibody in patients with metastatic prostate cancer: pharmacokinetics, biodistribution, dosimetry, and lesion uptake. J Nucl Med. 2016;57(12):1858–64. https://doi.org/10.2967/jnumed.116.176206.
Fox JJ, Gavane SC, Blanc-Autran E, Nehmeh S, Gönen M, Beattie B, et al. Positron emission tomography/computed tomography-based assessments of androgen receptor expression and glycolytic activity as a prognostic biomarker for metastatic castration-resistant prostate cancer. JAMA Oncol. 2018;4:217–24.
Wise DR, Schneider JA, Armenia J, Febles VA, McLaughlin B, Brennan R, et al. Dickkopf-1 can lead to immune evasion in metastatic castration-resistant prostate cancer. JCO Precis Oncol. 2020;4:1167–79. https://doi.org/10.1200/Po.20.00097.
Scott AM, Wiseman G, Welt S, Adjei A, Lee FT, Hopkins W, et al. A phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin Cancer Res. 2003;9(5):1639–47.
Welt S, Divgi CR, Scott AM, Garin-Chesa P, Finn RD, Graham M, et al. Antibody targeting in metastatic colon cancer: a phase I study of monoclonal antibody F19 against a cell-surface protein of reactive tumor stromal fibroblasts. J Clin Oncol. 1994;12(6):1193–203. https://doi.org/10.1200/JCO.1994.12.6.1193.
Giesel FL, Kratochwil C, Lindner T, Marschalek MM, Loktev A, Lehnert W, et al. 68Ga-FAPI PET/CT: biodistribution and preliminary dosimetry estimate of 2 DOTA-containing FAP-targeting agents in patients with various cancers. J Nucl Med. 2019;60:386–92.
Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, Cho H, et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature. 2010;467(7315):596–9. https://doi.org/10.1038/nature09454.
Fagin J. Personal communication. In: Larson SM. Sloan Kettering Institute, New York.
Ho AL, Grewal RK, Leboeuf R, Sherman EJ, Pfister DG, Deandreis D, et al. Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. N Engl J Med. 2013;368(7):623–32. https://doi.org/10.1056/NEJMoa1209288.
Fisher B, Packard BS, Read EJ, Carrasquillo JA, Carter CS, Topalian SL, et al. Tumor localization of adoptively transferred indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma. J Clin Oncol. 1989;7(2):250–61. https://doi.org/10.1200/JCO.1989.7.2.250.
Koehne G, Doubrovin M, Doubrovina E, Zanzonico P, Gallardo HF, Ivanova A, et al. Serial in vivo imaging of the targeted migration of human HSV-TK-transduced antigen-specific lymphocytes. Nat Biotechnol. 2003;21(4):405–13. https://doi.org/10.1038/nbt805.
Carrasquillo JA, Bunn PA, Keenan AM, Reynolds JC, Schroff RW, Foon KA, et al. Radioimmunodetection of cutaneous T-cell lymphoma with 111In-labeled T101 monoclonal antibody. N Engl J Med. 1986;315:673–80.
Tavare R, Escuin-Ordinas H, Mok S, McCracken MN, Zettlitz KA, Salazar FB, et al. An effective immuno-PET imaging method to monitor CD8-dependent responses to immunotherapy. Cancer Res. 2016;76(1):73–82. https://doi.org/10.1158/0008-5472.CAN-15-1707.
Lucignani G, Larson SM. Doctor, what does my future hold? The prognostic value of FDG-PET in solid tumours. Eur J Nucl Med Mol Imaging. 2010;37:1032–8.
Downey RJ, Akhurst T, Gonen M, Vincent A, Bains MS, Larson S, et al. Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection. J Clin Oncol. 2004;22(16):3255–60. https://doi.org/10.1200/JCO.2004.11.109.
Pandit N, Gonen M, Krug L, Larson SM. Prognostic value of [18F]FDG-PET imaging in small cell lung cancer. Eur J Nucl Med Mol Imaging. 2003;30(1):78–84. https://doi.org/10.1007/s00259-002-0937-8.
Cachin F, Prince HM, Hogg A, Ware RE, Hicks RJ. Powerful prognostic stratification by [18F]fluorodeoxyglucose positron emission tomography in patients with metastatic breast cancer treated with high-dose chemotherapy. J Clin Oncol. 2006;24(19):3026–31. https://doi.org/10.1200/JCO.2005.04.6326.
Robbins RJ, Wan Q, Grewal RK, Reibke R, Gonen M, Strauss HW, et al. Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. J Clin Endocrinol Metab. 2006;91(2):498–505. https://doi.org/10.1210/jc.2005-1534.
Pan L, Gu P, Huang G, Xue H, Wu S. Prognostic significance of SUV on PET/CT in patients with esophageal cancer: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2009;21(9):1008–15. https://doi.org/10.1097/MEG.0b013e328323d6fa.
Patronas NJ, Di Chiro G, Kufta C, Bairamian D, Kornblith PL, Simon R, et al. Prediction of survival in glioma patients by means of positron emission tomography. J Neurosurg. 1985;62:816–22.
Schöder H, Noy A, Gönen M, Weng L, Green D, Erdi YE, et al. Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin’s lymphoma. J Clin Oncol. 2005;23:4643–51.
Meirelles GS, Schoder H, Ravizzini GC, Gonen M, Fox JJ, Humm J, et al. Prognostic value of baseline [18F]fluorodeoxyglucose positron emission tomography and 99mTc-MDP bone scan in progressing metastatic prostate cancer. Clin Cancer Res. 2010;16(24):6093–9. https://doi.org/10.1158/1078-0432.CCR-10-1357.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 Springer Nature Switzerland AG
About this entry
Cite this entry
Larson, S.M. (2022). Cancer Biology of Molecular Imaging. In: Volterrani, D., Erba, P.A., Strauss, H.W., Mariani, G., Larson, S.M. (eds) Nuclear Oncology. Springer, Cham. https://doi.org/10.1007/978-3-031-05494-5_1
Download citation
DOI: https://doi.org/10.1007/978-3-031-05494-5_1
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-031-05493-8
Online ISBN: 978-3-031-05494-5
eBook Packages: MedicineReference Module Medicine